Adaptix Partners with Spartan Medical for U.S. Expansion
OXFORD, United Kingdom, and ST. PETERSBURG, Fla., July 20, 2026 Adaptix Ltd. announced a strategic U.S. distribution partnership with...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
OXFORD, United Kingdom, and ST. PETERSBURG, Fla., July 20, 2026 Adaptix Ltd. announced a strategic U.S. distribution partnership with...
DALLAS, July 8, 2026 Spectral AI, Inc. announced the appointment of Darcy Bajko as Chief Commercial Officer, effective July...
AMSTERDAM, Netherlands, July 8, 2026 Philips announced the launch of Alturion, a next-generation AI-powered ultrasound system designed to improve...
SAN FRANCISCO | July 9, 2026 Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, has announced...
VANCOUVER, British Columbia, July 6, 2026 Grey Matters Health Inc. announced the delivery of its first FDA-cleared CareMiBrainâ„¢ brain-dedicated...
SOPHIA ANTIPOLIS, France, July 2, 2026 Median Technologies has announced that its eyonis® LCS, an artificial intelligence (AI)-powered Software...
NEW YORK, June 25, 2026 Aidoc announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device...
MENLO PARK, Calif., June 10, 2026 Subtle Medical has received U.S. FDA clearance for SubtleHDâ„¢(CT), a new artificial intelligence-powered...
BERLIN, Germany, June 10, 2026 Vara has received CE Class IIb certification under the European Union Medical Device Regulation...
PLAINSBORO, New Jersey and BAGSVÆRD, Denmark, June 7, 2026 Novo Nordisk has reported compelling Phase 3 results demonstrating that...
